- Pfizer ties PD-1 drug to 32% bladder cancer risk reduction in mixed bag phase 3 as it misses secondaries Fierce Biotech
- Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer Yahoo Finance
- CREST: Significant EFS boost seen with sasanlimab plus BCG in NMIBC Urology Times
- Pfizer Stock Climbs Pre-Market On Bladder Cancer Trial Success: Retail Digests Data Ahead Of Q1 Print MSN
- Pfizer’s Subcutaneous PD-1 Cuts Risks in Bladder Cancer but Misses Survival Endpoint BioSpace